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Abstract
Background: The possibility of clearing Cell-free Plasma Hemoglobin (CPH) from human plasma may appear
attractive, especially when considering the noxious effects that CPH has on the immune function and the renal
damage caused by its filtration. The existence of the so-called High Cut-Off (HCO) filters, possessing pores as big as
60 kDa, could potentially allow the clearance of the αβ dimers (31.3 kDa), the form in which the α2β2 hemoglobin
tetramers (62.6 kDa) physiologically dissociate in plasma. We present herein the first reported case in which such an
attempt was made.
Case presentation: The patient was a 51-year-old man with hemolytic crisis due to glucose-6-phosphate
dehydrogenase deficiency, further complicated by pigment-induced nephropathy. He underwent a 48-h CVVHD
session, in which a HCO filter was used. The Sieving Coefficient (SC) for CPH was initially 0.08 and decreased to 0.02
after 24 h. This unexpected low SC was due to the initial high concentration of CPH (4.24 g/L). At such
concentrations, the α2β2 tetramer poorly dissociates into the αβ dimer; but increases exponentially at
concentrations lower than 1 g/L.
Conclusions: Clearance of CPH through a HCO filter is technically feasible but its performance markedly relies on
the initial concentration of CPH. Critically ill patients with smoldering hemolysis, as it happens during septic shock
or ECMO treatment, may benefit the most from the use of this membrane in order to clear CPH.
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Background
The presence of Cell-free Plasma Hemoglobin (CPH) in
human plasma derives from the erythrocytes breakdown
and depletion of haptoglobin, the plasmatic protein de-
voted to CPH scavenging. This usually occurs in massive
hemolysis, in the context of which haptoglobin-binding
capacity is exhausted and CPH is filtered by glomeruli.
The glomerular filtration of hemoglobin can lead to
pigmented-cast nephropathy, a fearsome complication
that may require urgent hemodialysis [1]. Apart from
the cases of massive hemolysis, CPH can also be found
in acutely ill patients with compromised liver function
because of a decreased production of haptoglobin as well
as in patients undergoing extracorporeal treatments like
hemodialysis and ECMO. In these cases, the CPH
concentration is just slightly higher with respect to the
physiological levels and is unable to cause significant
kidney damage. However, CPH presents some toxic
effects even at low levels, since it alters the pathogen-in-
duced inflammatory response. Animal models have dem-
onstrated that lipopolysaccharide (LPS)-induced release
of TNF-α is increased after exposure to CPH [2, 3].
Moreover, a clinical study clearly demonstrated that
CPH is a strong predictor of mortality in septic patients
[4]. Therefore, the possibility to dialyze CPH in septic
patients may represent an intriguing topic of research in
the next future. Recently, an in-vitro proof-of-concept
model demonstrated that a High-Cut Off (HCO)
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hemofilter with pores of 60 kDa diameter is able to
dialyze the αβ hemoglobin dimer, whose molecular
weight is 31.3 kDa [5]. The dimer is that part of the
hemoglobin molecule that is actually filtered by the
glomerulus and that eventually causes pigmented-cast
nephropathy [6]. The tetramer composed by two α and
two β subunits, which is the physiological carrier of
oxygen within erythrocytes, weighs instead 62.6 kDa; this
is scarcely filtered by the glomerulus and by HCO filters.
Thus, clearance of CPH depends on the dissociation
degree of Hb tetramers into dimers. To the best of our
knowledge, we report the first case of a patient with
massive hemolysis and Acute Kidney Injury (AKI)
treated with a HCO filter that allowed us to verify the
possibility to clear CPH in-vivo from human plasma.
Case presentation
A 51-year-old man presented to the emergency depart-
ment with fever, abdominal pain and jaundice. Past and
recent medical history were unremarkable and the patient
did not report any recent trip, risky sexual behaviour,
parenteral drug intake or ingestion of potentially contami-
nated food. The physical examination revealed right hypo-
chondrium and epigastric tenderness and no signs of
peritonitis. Lab tests showed Aspartate AminoTransferase
(AST) 3560 UI/L, Alanine AminoTransferase (ALT) 4513
UI/L, hyperbilirubinemia (total 16 mg/dL), alkaline
phosphatase, GGT 90/418 UI/L, PT 50%, normal pancre-
atic enzymes and normal renal function. Abdominal
ultrasound showed no alterations.
Twenty-four hours after the admission, liver function
rapidly declined, with PT 40% and maximum total bilirubin
of 47 mg/dL. In parallel, blood test showed an elevation of
LDH, haptoglobin consumption, reticulocytosis and AKI
stage 3 with creatinine of 4 mg/dL and a peripheral blood
smear suggestive of hemolysis. Urinalysis was positive for
bilirubin and hemoglobin, while the urinary sediment
discarded the presence of red blood cells. Serological tests
were positive for IgM Hepatitis A Virus (HAV). In addition,
a previously unknown complete glucose-6-phosphate
dehydrogenase deficiency was detected.
On the basis of these findings a diagnosis of acute
hepatitis A infection complicated with massive hemolysis
due to glucose-6-phosfate dehydrogenase deficiency was
done. Hemolysis was probably triggered by fitomenadione
administration and its diagnosis was partially masked by
high bilirubin levels due to the severe hepatitis. AKI was
interpreted as the result of pigmented-cast nephropathy.
The haemolytic crisis was initially managed with 2 sessions
of plasma exchange. However, considering the need of
dialysis and the presence of CPH, continuous renal replace-
ment treatment with a HCO filter (Septex™, 1.1m2,
Gambro-Baxter, Hechingen, Germany; Fig. 1) in CVVHD
modality was started. In order to measure the CPH
clearance, plasma was collected in EDTA tubes from arterial,
venous and dialysate ports of the CRRT circuit and CPH
was measured with Drabkin-based spectrophotometric ana-
lysis at 540 nm. The Sieving coefficient (SC) was calculated
as CD/[CIn +COut)/2] where CD, CIn and COut represent
CPH concentration at the dialysate, blood inlet and blood
outlet side. CPH clearance was calculated as {CD/[CIn +
COut)/(2)]}Qe, where Qe is the effluent flow. This filter was
used for 48 h, observing a CPH value of 4,24 g/L at the
beginning and of 3,72 g/L at the end of the treatment.
The calculated SC for CPH was 0.08 at treatment start,
later decreasing to 0.02 after 24 h. The calculated
clearance of CPH declined as well, from 2,87 ml/min
on the first day to 0,76 ml/min after 24 h (Table 1 for
treatment data and CPH clearance profile, Table 2 for
common laboratory data before and after CVVHD
treatment).
After this treatment, as the patient was still oliguric,
seven sessions more of intermittent hemodialysis were
performed. Eventually, 4 weeks after admission urine
output ensued and the patient’s renal function started
to recover. At the time of discharge, total bilirubin was
3.4 mg/dL and creatinine 2.8 mg/dL. Finally, 3 months
after discharge the patient presented normal renal and
hepatic function.
Fig. 1 Effluent bag during the first day of therapy. The brownish
hue depends on the presence of high bilirubin levels (yellow) along
with the filtered CPH (red)
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Discussion and conclusions
To the best of our knowledge, we report the first case of
in-vivo CPH clearance by means of HCO-based CVVHD
treatment. HCO filters have been designed to improve
clearance of middle-sized molecules that were not previ-
ously cleared by normal filters, such as pro- and
anti-inflammatory cytokines [7–10]. The possibility to clear
CPH has been recently examined in an in-vitro model, in
which the authors demonstrated the efficacy of the same
HCO filter that we used, with a SC for CPH of 0.35 and a
clearance of approximately 22 ml/min [5]. However, in our
case the initial SC was of only 0.08, decreasing to 0.02 in
the following 24 h, presumably due to the phenomenon of
protein-coating. CPH clearance was reduced as well, with
values below 3 ml/min initially: albeit not negative, this
clearance is far from being clinically relevant. In order to
explain the striking difference with the results obtained in
the in-vitro model, we should consider the dissociation char-
acteristics of the hemoglobin tetramers (62.6 kDa) into di-
mers (31.3 kDa). Indeed, the hemoglobin dimer is the part
of the molecule that is cleared by the HCO filter under
study, whose cut-off is 60 kDa. As the dissociation of
tetramers into dimers is maximum at low concentrations of
CPH, the best results are obtained with CPH concentrations
lower than 1 g/L. In the above-cited in-vitro study, indeed,
the CPH concentration was within this range and the ap-
proximate dissociation degree at this concentration was
around 40%. On the other side, our patient had much higher
CPH concentration (4.24 g/L). At this level, the expected
dissociation degree is lower than 10% [5]. Therefore, the
lower SC for CPH observed in our case is probably due to
the lesser degree of dissociation of the molecule. This point
provides an important indication, since it demonstrates that
those patients that would benefit the most from this treat-
ment are those presenting CPH levels lower than 1 g/L.
Presumably, patients with massive hemolysis and already
established kidney injury are less likely to benefit from
HCO-based CPH clearance. On the other side, critically ill
patients with smoldering hemolysis and lower concentra-
tions of CPH should theoretically take more advantage from
it. For example, pediatric patients submitted to two different
types of ECMO treatment had mean CPH values between
0.36 and 0.58 g/l [11], while CPH values in septic patients
ranged from 0.034 to 0.185 g/L [4]. It is worthy to underline
that even these low levels of CPH are not harmless. In a rat
model, purified hemoglobin enhanced TNF-α synthesis in
LPS-stimulated macrophages by a factor of 1.000 [2]. In
another model, the administration of hemoglobin in
LPS-treated mice resulted in an increase in TNF-α levels
and mortality [3]. In humans, CPH was strongly associ-
ated with decreased survival in severe septic patients, even
after substantial correction with already known risk fac-
tors including age, inflammatory biomarkers, Simplified
Acute Physiology (SAPS-II) and Sequential Organ Failure
Assessment (SOFA) scores [4].
Conclusion
In conclusion, we report the case of a patient treated with
a HCO-based CRRT treatment for the clearance of CPH.
The lower than expected SC was probably due to the low
dissociation of the hemoglobin tetramers into dimers, as a
consequence of the high concentrations of CPH in our pa-
tient. Therefore, we might infer that those patients that
would benefit the most from this kind of treatment are
the critically ill ones with low levels of CPH in the context
of septic shock or extracorporeal treatments like ECMO.
Even at these low levels, CPH has well-documented harm-
ful effects on the immune system. The possibility to clear
CPH in these patients may not represent only a “cosmetic”
Table 1 Treatment data and CPH concentrations 30′, 24 h and
48 h after CRRT start
30 min 24 h 48 h
CIn (g/L) 4,24 4,33 3,72
COut (g/L) 4,23 4,19 3,66
CD (g/L) 0,37 0,1 0,07
Sieving Coefficient 0,087 0,023 0,018
Clearance (ml/min) 2,87 0,76 0,62
Qb (ml/min) 250 250 250
Qd (ml/min) 33 33 33
Qe (ml/Kg/h) 28,2 29 29
UF (ml/h) 0 50 50
CIn CPH concentration at the arterial side, COut CPH concentration at the
venous side, CD CPH concentration at dialysate side, Qb blood flow, Qd
dialysate flow, Qe effluent flow, UF UltraFiltration rate
Table 2 Main laboratory values before and after 48-h long
treatment with the HCO membrane
Before HCO-CVVHD After HCO-CVVHD
Creatinine (mg/dL) 6.48 3.55
AST/ALT (UI/L) 196/314 106/208
Alkaline Phosphatase (UI/L) 66 89
Gamma-GT (UI/L) 51 111
Direct Bilirubine (mg/dL) 31.2 24.2
Indirect Bilirubine (mg/dL) 4.8 4
Haptoglobine (g/L) Undetectable 0.54
C-Reactive Protein (mg/dL) 6.48 5.89
Na/K (mEq/L) 140/4.4 137/4
Albumin (g/L) 28 28
Total protein (g/L) 41 50
Hemoglobin (g/L) 81 108
Platelets (× 103/L) 192 177
White Blood Cells (×103/L) 13.53 7.29
Prothrombin Time (%) 69.7 59.9
Cucchiari et al. BMC Nephrology  (2018) 19:250 Page 3 of 4
intervention, but may also be beneficial in blunting the in-
flammatory response.
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